

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

HighResÂ® and Waters collaborate to advance drug discovery through robotic automation

24 June 2026 | News

To enable higher-throughput studies and improve reproducibility



HighRes® has announced a strategic collaboration to enable robotic capabilities on Waters Biosciences, formerly BD Biosciences, flow cytometers to automate key experimental steps and streamline research workflows, from basic research to drug discovery.

The companies are integrating the BD FACSLyric™ Flow Cytometer with the HighRes Nucleus® Automation and Cellario® Software Platforms, enabling scientists to utilise robotic arm capabilities to run reliable, complex, multi-step experiments unattended with continuous operation of up to three times more experimental runs per day. The integration enables higher-throughput studies, improves reproducibility, and allows for greater operational efficiency.

"The BD FACSLyric™ Flow Cytometer, when paired with HighRes automation, is an ideal solution for laboratories running complex flow cytometry studies that demand scale and precision, including for higher volumes of experiments," said Eric Diebold, Vice President and General Manager, Instruments & informatics, Waters Biosciences, Waters Corporation. "This collaboration exemplifies our long-term commitment to advancing robotic automation across our complete portfolio of flow cytometers, unlocking a new dimension of automation for research and biopharma partners aiming to bring their potentially life-changing therapies to market even faster."

"With this collaboration, scientists can run more experiments per day with consistent quality, reduce hands-on time from hours to minutes, and design assays that were previously too complex or time-sensitive to automate – with every step tracked for complete data integrity and reproducibility," said Ira Hoffman, CEO, HighRes. "By combining BD's expertise in flow cytometry and HighRes' leadership in lab automation, we are enabling more labs around the world to operate with true end-to-end confidence."